ABCL vs URGN: which is the better buy in 2026?
On Alexandria's Compass, UroGen Pharma Ltd. has the edge with a 90/100 score versus 89/100 for ABCL. Here is how they stack up, factor by factor.
AbCellera Biologics Inc.
NASDAQ:ABCL
Antibody discovery factory pivoting to owning the drugs it finds, with two Phase 1/2 readouts that could re-rate the whole thesis.
Full ABCL analysisUroGen Pharma Ltd.
NASDAQ:URGN
Zusduri is rewriting how urologists treat bladder cancer, and the early script data is louder than the share price suggests.
Full URGN analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is ABCL or URGN the better buy in 2026?
By Compass Score, UroGen Pharma Ltd. (NASDAQ:URGN) edges it at 90/100 versus 89/100 for ABCL. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare ABCL and URGN?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.